HSIC Stock Likely to Gain From Its Latest Acquisition of Acentus

Zacks11-21 21:48

Henry Schein, Inc. HSIC recently entered into an agreement to acquire Acentus, a national medical supplier that specializes in delivering Continuous Glucose Monitors (CGMs). Henry Schein anticipates ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2485413229?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/KEj1lCkxRqndrrMrF3m.HA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c7450ec9df154559fbeb393640d6629","is_english":true,"pubTime":"2024-11-21 21:48","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2485413229","market":"us","top_or_hot":-1,"title":"HSIC Stock Likely to Gain From Its Latest Acquisition of Acentus","media":"Zacks","content":"<div>\n<p>Henry Schein, Inc. HSIC recently entered into an agreement to acquire Acentus, a national medical supplier that specializes in delivering Continuous Glucose Monitors (CGMs). Henry Schein anticipates ...</p>\n\n<a href=\"https://finance.yahoo.com/news/hsic-stock-likely-gain-latest-134800663.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HSIC Stock Likely to Gain From Its Latest Acquisition of Acentus</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHSIC Stock Likely to Gain From Its Latest Acquisition of Acentus\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-21 21:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/hsic-stock-likely-gain-latest-134800663.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Henry Schein, Inc. HSIC recently entered into an agreement to acquire Acentus, a national medical supplier that specializes in delivering Continuous Glucose Monitors (CGMs). Henry Schein anticipates ...</p>\n\n<a href=\"https://finance.yahoo.com/news/hsic-stock-likely-gain-latest-134800663.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RMD.AU","symbol_name":"Resmed DRC","start_time":0,"source_url":"https://finance.yahoo.com/news/hsic-stock-likely-gain-latest-134800663.html","article_id":"2485413229","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/KEj1lCkxRqndrrMrF3m.HA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c7450ec9df154559fbeb393640d6629"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2485413229","pubTimestamp":1732196880,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Henry Schein, Inc. HSIC recently entered into an agreement to acquire Acentus, a national medical supplier that specializes in delivering Continuous Glucose Monitors . Henry Schein anticipates the transaction to be neutral to 2024 non-GAAP earnings per share and accretive thereafter. The transaction is expected to be completed in the first quarter of 2025. Financial terms have not been disclosed.Following the announcement, shares of HSIC moved south 1.5% to $73.73 yesterday. The company is gaining a high level of synergies from its strategic acquisitions within the homecare medical supplies space. Henry Schein acquired Prism Medical Products, LLC, in 2021, and Shield Healthcare and Mini Pharmacy in 2023. With the latest acquisition of Acentus, Henry Schein’s homecare medical products platform will now have an annual revenue base of approximately $350 million. Accordingly, we expect market sentiment to turn in favor of HSIC in the upcoming days.In the same month, the company’s dental so","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"RMD.AU":"Resmed DRC","LU2177674079.SGD":"Fidelity Asia Pacific Opportunities A-ACC-SGD (hedged)","LU2065732104.USD":"ALLSPRING (LUX) WF GLOBAL SMALL CAP EQUITY \"I\" (USD) ACC","LU0205193047.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD)  ACC","BK4504":"桥水持仓","BK4548":"巴美列捷福持仓","BK4175":"保健护理产品经销商","CAGR":"California Grapes International, Inc.","LU0205194284.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD) INC AV","BK4567":"ESG概念","GMED":"Globus Medical Inc","BK4585":"ETF&股票定投概念","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","IE00BLDYK493.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) INC","RMD":"瑞思迈","BK4159":"经销商","BK4082":"医疗保健设备","LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","BK4588":"碎股","LU2008162690.USD":"FIDELITY FUNDS - ASIA PACIFIC OPPORTUNITIES \"A\" (USD) ACC","IE00B64QTZ34.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) ACC","BK4198":"医疗保健用品","HSIC":"汉瑞祥","HAE":"美国血液技术"},"translate_title":"HSIC股票可能会从最新收购Acentus中受益","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RMD.AU":0.9,"RMD":0.6,"HSIC":0.6,"HAE":0.6,"GMED":0.6,"CAGR":0.6},"content_text":"Henry Schein, Inc. HSIC recently entered into an agreement to acquire Acentus, a national medical supplier that specializes in delivering Continuous Glucose Monitors (CGMs). Henry Schein anticipates the transaction to be neutral to 2024 non-GAAP earnings per share and accretive thereafter. The transaction is expected to be completed in the first quarter of 2025. Financial terms have not been disclosed.\nHSIC’s Likely Stock Trend Following the News\nFollowing the announcement, shares of HSIC moved south 1.5% to $73.73 yesterday.  The company is gaining a high level of synergies from its strategic acquisitions within the homecare medical supplies space. Henry Schein acquired Prism Medical Products, LLC, in 2021, and Shield Healthcare and Mini Pharmacy in 2023. With the latest acquisition of Acentus, Henry Schein’s homecare medical products platform will now have an annual revenue base of approximately $350 million. Accordingly, we expect market sentiment to turn in favor of HSIC in the upcoming days. \nHSIC currently has a market capitalization of $9.19 billion. Estimates for 2024 earnings have moved north 0.6% to $4.77 in the past 30 days. Its earnings surpassed estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 2.85%.\nMore on HSIC’s Acquisition Agreement\nAs health care in the United States is increasingly being provided in home-based settings, Henry Schein’s strategic acquisition of Acentus aims to expand its offerings to meet the growing demand. \nWith the latest acquisition, Henry Schein expects to strengthen its position nationally in the home medical supply market and better serve its valued customers, including clinics, physician practices, health systems, and ambulatory surgery centers. \nAfter the transaction is closed, Acentus’ founders — Brett Carroll, Todd Cianfrocca, Greg Duvall and Julio Valdivia — will join Henry Schein. For investors’ information, Acentus has  annual revenues of approximately $35 million and is headquartered in Tampa, FL. \nIndustry Prospects Favor HSIC\nAccording to a Grand View Research report, the global home healthcare market was valued at $390.24 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 7.96% from 2024 to 2030. Key factors contributing to the market growth include rising demand for cost-effective alternatives to curb rising healthcare costs and growing penetration of the virtual and remote care industry.\nOther Recent Developments by HSIC\nLast month, the company launched Henry Schein Marketplace, a new online service offering more than 8,000 non-clinical products to dental customers.\nImage Source: Zacks Investment Research\nIn the same month, the company’s dental software business, Henry Schein One, signed a partnership with Bridge to develop and launch axiUm Engage — a platform designed to streamline workflows for academic and dental care organizations. The collaboration is aimed at empowering dental schools and care organizations with better patient engagement tools and efficient data management.\nHSIC’s Price Performance\nIn the past year, shares of HSIC have risen 6.2% compared with the industry’s 7.% growth. \nHSIC’s Zacks Rank and Key Picks\nHSIC currently carries a Zacks Rank #3 (Hold).\nSome better-ranked stocks in the broader medical space are Haemonetics HAE, Globus Medical GMED and ResMed RMD. While ResMed sports a Zacks Rank #1 (Strong Buy) at present, Haemonetics and Globus Medical carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.\nHaemonetics has an earnings yield of 5.02% compared with the industry’s 1.18%. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 19.39%. Its shares have risen 1.8% compared with the industry’s 23.1% growth in the past year. Estimates for Haemonetics’ 2025 EPS have moved north 0.4% to $4.59 in the past 30 days. \nEstimates for Globus Medical’s 2024 EPS have remained constant at $2.84 in the past 30 days. Shares of the company have surged 60.6% in the past year compared with the industry’s growth of 32.7%. GMED’s earnings surpassed estimates in each of the trailing four quarters, the average beat being 12.1%. In the last reported quarter, it delivered an earnings surprise of 10.3%.\nEstimates for ResMed’s fiscal 2025 EPS have risen 2.7% in the past 30 days. Shares of the company have surged 86.3% in the past year compared with the industry’s 32.1% growth. RMD’s earnings surpassed estimates in each of the trailing four quarters, the average beat being 6.4%. In the last reported quarter, it delivered an earnings surprise of 8.4%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nResMed Inc. (RMD) : Free Stock Analysis Report\nHenry Schein, Inc. (HSIC) : Free Stock Analysis Report\nHaemonetics Corporation (HAE) : Free Stock Analysis Report\nGlobus Medical, Inc. (GMED) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Company Corporation","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2485413229"}